Blood Clots Clinical Trials

Find Blood Clots Clinical Trials Near You

Multicenter External Validation of the APTTO Predictive Model Based on Clot Waveform Analysis for the Assessment of Prolonged Activated Partial Thromboplastin Time

Status: Recruiting
Location: See all (16) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic disorders. Clot waveform analysis (CWA), automatically generated during routine APTT testing by optical coagulation analyzers, provides additional quantitative and qualitative information on clot formation dynamics. The APTTO model is a previously developed two-step predictive algorithm based on CWA features designed to estimate the probability of a pathological cause of prolonged APTT and to differentiate lupus anticoagulant from intrinsic pathway factor deficiency or von Willebrand disease. Internal validation has demonstrated good discrimination and calibration. This multicenter observational study aims to perform an external validation of the APTTO model in independent patient cohorts, assessing its discrimination, calibration, and decision-analytic performance without model updating.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patients of any age (pediatric and adult populations) undergoing coagulation testing with:

• \- Prolonged activated partial thromboplastin time (APTT), defined as an APTT ratio ≥ 1.25.

• \- Normal prothrombin time (PT), according to local laboratory reference ranges.

• Availability of clot waveform analysis (CWA) data obtained during routine APTT testing using:

‣ Optical coagulation analyzers (ACL TOP platform).

⁃ Silica-based APTT reagent (SynthASil®).

• Completion of the standard laboratory evaluation for prolonged APTT as part of routine clinical care, when clinically indicated.

• Samples collected and processed in accordance with the standardized preanalytical protocol defined in the study SOP.

• Patients evaluated in either:

‣ Preoperative assessment, or

⁃ Routine clinical practice (non-preoperative setting).

Locations
Other Locations
Spain
Hospital de la Santa Creu i Sant Pau
NOT_YET_RECRUITING
Barcelona
Hospital Universitario Severo Ochoa
NOT_YET_RECRUITING
Leganés
Hospital Universitario Arnau De Vilanova
NOT_YET_RECRUITING
Lleida
Hospital Universitario 12 de Octubre
NOT_YET_RECRUITING
Madrid
Hospital Universitario Clínico San Carlos
NOT_YET_RECRUITING
Madrid
Hospital Universitario Fundación Jiménez Díaz
RECRUITING
Madrid
Hospital Universitario Gregorio Marañón
NOT_YET_RECRUITING
Madrid
Hospital Universitario Puerta de Hierro
NOT_YET_RECRUITING
Madrid
Hospital Universitario Ramón y Cajal
NOT_YET_RECRUITING
Madrid
Hospital Clínico Universitario Virgen de la Arrixaca
NOT_YET_RECRUITING
Murcia
Clínica Universidad de Navarra
NOT_YET_RECRUITING
Pamplona
Hospital Clínico Universitario de Salamanca
NOT_YET_RECRUITING
Salamanca
Complexo Hospitalario Universitario de Santiago
NOT_YET_RECRUITING
Santiago De Compostela
Hospital Clínico Universitario de Valladolid
NOT_YET_RECRUITING
Valladolid
Complexo Hospitalario Universitario De Vigo
NOT_YET_RECRUITING
Vigo
Hospital Clínico Universitario Lozano Blesa
NOT_YET_RECRUITING
Zaragoza
Contact Information
Primary
Diego Velasco Rodríguez, MD, PhD
diego.velascor@quironsalud.es
+34 669 98 04 32
Time Frame
Start Date: 2026-01-13
Estimated Completion Date: 2027-03
Participants
Target number of participants: 1500
Treatments
Patients with prolonged activated partial thromboplastin time (APTT)
Patients with prolonged activated partial thromboplastin time (APTT) and normal prothrombin time undergoing routine laboratory evaluation. Clot waveform analysis (CWA) data and clinical information are collected prospectively as part of standard care and analyzed using the APTTO predictive models. No additional diagnostic or therapeutic procedures are performed.
Sponsors
Leads: Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

This content was sourced from clinicaltrials.gov